دورية أكاديمية
أعرض في EDS

The Effect of Intra-articular Hypertonic Dextrose Prolotherapy on Pain, Quality of Life, and Functional Outcomes Scores in Patients With Knee Osteoarthritis.

التفاصيل البيبلوغرافية
العنوان: The Effect of Intra-articular Hypertonic Dextrose Prolotherapy on Pain, Quality of Life, and Functional Outcomes Scores in Patients With Knee Osteoarthritis.
المؤلفون: Vomer RP 2nd; Family Medicine, Mayo Clinic Jacksonville Campus, Jacksonville, USA.; Family Medicine and Community Health, Duke University, Durham, USA., Larick RS; Physical Medicine and Rehabilitation, Eastern Virginia Medical School, Norfolk, USA., Milon R; Sports Medicine, Mayo Clinic Jacksonville Campus, Jacksonville, USA., York E; Family Medicine, Prisma Health University of South Carolina, Columbia, USA.
المصدر: Cureus [Cureus] 2023 Nov 01; Vol. 15 (11), pp. e48096. Date of Electronic Publication: 2023 Nov 01 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Introduction Knee osteoarthritis is a common chronic condition leading to pain and debility. Prolotherapy is a safe and cost-effective treatment option. Our team conducted a case series to examine the effect of prolotherapy on functional measures and quality of life in patients with knee osteoarthritis. Methods Our case series included 15 total patients consisting of male and female patients aged 50-85 years old with a prior diagnosis of knee osteoarthritis and moderate pain. The patients completed baseline Western Ontario and McMaster Universities Arthritis Index (WOMAC) and EuroQol-5 Dimension (EQ5D) surveys and received an ultrasound-guided intra-articular prolotherapy injection. The patients were then followed up by Telehealth at one-, two-, and three-month post-procedure. Results Data points for 15 patients were recorded over the duration of the three months. Results revealed significantly improved functional scores from the baseline period (M = 0.60) to the one-month (M = 0.43), two-month (M = 0.48), and three-month (M = 0.46), observed power = 0.99. Participants reported significantly lower pain scores between the baseline period (M = 0.60) compared to the one-month (M = 0.34), two-month (M = 0.35) and three-month (M = 0.39) periods. There was no statistical significance across time in participants' EQ5D scores. The repeated-measures analysis of variance (ANOVA) revealed no statistically significant differences in participants scores between the baseline (M = 64.4), one-month (M = 68.93), two-month (M = 68.47), or three-month (M = 68.33), observed power = 0.31. There were no statistically significant differences in participants WOMAC stiffness scores between the baseline (M = 0.67), one-month (M = 0.46), two-month (M = 0.57), or three-month (M = 0.56) periods, observed power = 0.73. The results revealed no significant change in participants' EQ5D and WOMAC stiffness scores. The results support a statistically significant improvement in patients' self-reported functioning and pain scores between the baseline and one-month, two-month, and three-month periods. Discussion The significant improvement in function occurred between the baseline and one-month time periods and the pain reduction was sustained throughout the two-month and three-month periods. Our study supports prolotherapy as an effective treatment option to improve pain and function in knee osteoarthritis. The study could be repeated with a large sample size to further investigate the effects of prolotherapy on quality-of-life measures.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2023, Vomer et al.)
References: Ann Fam Med. 2013 May-Jun;11(3):229-37. (PMID: 23690322)
Phys Med Rehabil Clin N Am. 2016 Nov;27(4):783-823. (PMID: 27788902)
Evid Rep Technol Assess (Full Rep). 2007 Sep;(157):1-157. (PMID: 18088162)
Clinics (Sao Paulo). 2022 May 17;77:100037. (PMID: 35594623)
J Clin Orthop Trauma. 2021 May 20;19:108-117. (PMID: 34046305)
Nat Rev Rheumatol. 2016 Feb;12(2):92-101. (PMID: 26439406)
J Neurol Neurosurg Psychiatry. 2000 Jul;69(1):67-73. (PMID: 10864606)
Osteoarthritis Cartilage. 2022 Feb;30(2):184-195. (PMID: 34534661)
N Engl J Med. 2006 Feb 23;354(8):841-8. (PMID: 16495396)
Arthritis Rheum. 2001 Oct;45(5):453-61. (PMID: 11642645)
Curr Rheumatol Rep. 2017 Jun;19(6):34. (PMID: 28484944)
Am J Phys Med Rehabil. 2022 Sep 1;101(9):816-825. (PMID: 34740224)
Ann Fam Med. 2020 May;18(3):235-242. (PMID: 32393559)
Perm J. 2017;21:16-183. (PMID: 29035179)
Pain Res Manag. 2020 Feb 18;2020:3873098. (PMID: 32148599)
Ther Adv Musculoskelet Dis. 2015 Apr;7(2):35-44. (PMID: 25829954)
Orthop Rev (Pavia). 2022 May 31;14(4):33921. (PMID: 35769650)
فهرسة مساهمة: Keywords: chronic pain management; functional improvement; osteoarthritis (oa); prolotherapy; quality of life (qol)
تواريخ الأحداث: Date Created: 20231204 Latest Revision: 20231205
رمز التحديث: 20231205
مُعرف محوري في PubMed: PMC10690838
DOI: 10.7759/cureus.48096
PMID: 38046716
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.48096